Stone, M.A., Charpentier, G., Doggen, K., Kuss, O., Lindblad, U., Kellner, C., et al. Quality of care of people with type 2 diabetes in eight European countries: findings from the Guideline Adherence to Enhance Care (GUIDANCE) study. Diabetes Care 36 (2013), 2628–2638.
Reaven, G.M., Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37 (1988), 1595–1607.
DeFronzo, R.A., Ferrannini, E., Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 14 (1991), 173–194.
Oliveras, A., de la Sierra, A., Resistant hypertension: patient characteristics, risk factors, co-morbidities and outcomes. J Hum Hypertens 28 (2014), 213–217.
White, W.B., Turner, J.R., Sica, D.A., Bisognano, J.D., Calhoun, D.A., Townsend, R.R., et al. Detection, evaluation, and treatment of severe and resistant hypertension: proceedings from an American Society of Hypertension Interactive forum held in Bethesda. J Am Soc Hypertens 8 (2014), 743–757.
Muxfeldt, E.S., de Souza, F., Salles, G.F., Resistant hypertension: a practical clinical approach. J Hum Hypertens 27 (2013), 657–662.
Bangalore, S., Davis, B.R., Cushman, W.C., Pressel, S.L., Muntner, P.M., Calhoun, D.A., et al. Treatment-resistant hypertension and outcomes based on randomized treatment group in ALLHAT. Am J Med 130 (2017), 439–489.
Ferrannini, E., Cushman, W.C., Diabetes and hypertension: the bad companions. Lancet 380 (2012), 601–610.
Scheen, A.J., Pharmacotherapy of “treatment resistant” type 2 diabetes. Expert Opin Pharmacother 18 (2017), 503–515.
American Diabetes Association, Standards of medical care in diabetes. Diabetes Care 40 (2017), S1–S135.
Inzucchi, S.E., Bergenstal, R.M., Buse, J.B., Diamant, M., Ferrannini, E., Nauck, M., et al. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 58 (2015), 429–442.
Garber, A.J., Abrahamson, M.J., Barzilay, J.I., Blonde, L., Bloomgarden, Z.T., Bush, M.A., et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm-2016 executive summary. Endocr Pract 22 (2016), 84–113.
Bejan-Angoulvant, T., Cornu, C., Archambault, P., Tudrej, B., Audier, P., Brabant, Y., et al. Is HbA1c a valid surrogate for macrovascular and microvascular complications in type 2 diabetes?. Diabetes Metab 41 (2015), 195–201.
Crowley, M.J., Holleman, R., Klamerus, M.L., Bosworth, H.B., Edelman, D., Heisler, M., Factors associated with persistent poorly controlled diabetes mellitus: clues to improving management in patients with resistant poor control. Chronic Illn 10 (2014), 291–302.
Yin, J., Yeung, R., Luk, A., Tutino, G., Zhang, Y., Kong, A., et al. Gender, diabetes education, and psychosocial factors are associated with persistent poor glycemic control in patients with type 2 diabetes in the Joint Asia Diabetes Evaluation (JADE) program. J Diabetes 8 (2016), 109–119.
Aronson, R., Orzech, N., Ye, C., Goldenberg, R., Brown, V., Specialist-led diabetes registries and predictors of poor glycemic control in type 2 diabetes: Insights into the functionally refractory patient from the LMC Diabetes Registry database. J Diabetes 8 (2016), 76–85.
Khan, H., Lasker, S.S., Chowdhury, T.A., Exploring reasons for very poor glycaemic control in patients with Type 2 diabetes. Prim Care Diabetes 5 (2011), 251–255.
Abdelmoneim, A.S., Eurich, D.T., Light, P.E., Senior, P.A., Seubert, J.M., Makowsky, M.J., et al. Cardiovascular safety of sulphonylureas: over 40 years of continuous controversy without an answer. Diabetes Obes Metab 17 (2015), 523–532.
International Diabetes Federation (IDF), Clinical Guidelines Task Force. Global guideline for type 2 diabetes. 2012 https://www.idf.org/sites/default/files/IDF-Guideline-for-Type-2-Diabetes.pdf [Accessed April 5, 2017].
National Institute for Health and Care Excellence (NICE), Type 2 diabetes in adults: management. 2016 http://www.nice.org.uk/guidance/ng28 [Accessed April 5, 2017].
Haute Autorité de Santé (HAS), Stratégie médicamenteuse du contrôle glycémique du diabète de type 2: recommandations. 2013 https://www.has-sante.fr/portail/upload/docs/application/pdf/2013-02/10irp04_reco_diabete_type_2.pdf [Accessed April 5, 2017].
Palmer, S.C., Mavridis, D., Nicolucci, A., Johnson, D.W., Tonelli, M., Craig, J.C., et al. Comparison of clinical outcomes and adverse events associated with glucose-lowering drugs in patients with type 2 diabetes: a meta-analysis. JAMA 316 (2016), 313–324.
McIntosh, B., Cameron, C., Singh, S.R., Yu, C., Dolovich, L., Houlden, R., Choice of therapy in patients with type 2 diabetes inadequately controlled with metformin and a sulphonylurea: a systematic review and mixed-treatment comparison meta-analysis. Open Med 6 (2012), e62–e74.
Zhong, X., Zhang, T., Liu, Y., Wei, X., Zhang, X., Qin, Y., et al. Effects of three injectable antidiabetic agents on glycaemic control, weight change and drop-out in type 2 diabetes suboptimally controlled with metformin and/or a sulfonylurea: A network meta-analysis. Diabetes Res Clin Pract 109 (2015), 451–460.
Polonsky, W.H., Fisher, L., Guzman, S., Villa-Caballero, L., Edelman, S.V., Psychological insulin resistance in patients with type 2 diabetes: the scope of the problem. Diabetes Care 28 (2005), 2543–2545.
Ross, S.A., Tildesley, H.D., Ashkenas, J., Barriers to effective insulin treatment: the persistence of poor glycemic control in type 2 diabetes. Curr Med Res Opin 27:3 (2011), 13–20.
Petrak, F., Stridde, E., Leverkus, F., Crispin, A.A., Forst, T., Pfutzner, A., Development and validation of a new measure to evaluate psychological resistance to insulin treatment. Diabetes Care 30 (2007), 2199–2204.
Wang, H.F., Yeh, M.C., Psychological resistance to insulin therapy in adults with type 2 diabetes: mixed-method systematic review. J Adv Nurs 68 (2012), 743–757.
Cramer, J.A., A systematic review of adherence with medications for diabetes. Diabetes Care 27 (2004), 1218–1224.
Bailey, C.J., Kodack, M., Patient adherence to medication requirements for therapy of type 2 diabetes. Int J Clin Pract 65 (2011), 314–322.
Grimaldi, A., Penfornis, A., Consoli, S., Falissard, B., Eymard, E., Williams, P., et al. Breaking barriers to effective type 2 diabetes management: findings from the use of the OPTIMA(c) questionnaire in clinical practice. Adv Ther 33 (2016), 1033–1048.
Reach, G., Pechtner, V., Gentilella, R., Corcos, A., Ceriello, A., Clinical inertia and its impact on treatment intensification in people with type 2 diabetes mellitus. Diabetes Metab, 43, 2017.
Grant, R., Adams, A.S., Trinacty, C.M., Zhang, F., Kleinman, K., Soumerai, S.B., et al. Relationship between patient medication adherence and subsequent clinical inertia in type 2 diabetes glycemic management. Diabetes Care 30 (2007), 807–812.
Reach, G., Patient non-adherence and healthcare-provider inertia are clinical myopia. Diabetes Metab 34 (2008), 382–385.
Khunti, K., Wolden, M.L., Thorsted, B.L., Andersen, M., Davies, M.J., Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people. Diabetes Care 36 (2013), 3411–3417.
Halimi, S., Balkau, B., Attali, C., Detournay, B., Amelineau, E., Blickle, J.F., Therapeutic management of orally treated type 2 diabetic patients, by French general practitioners in 2010: the DIAttitude Study. Diabetes Metab 38:Suppl 3 (2012), S36–S46.
Kunt, T., Snoek, F.J., Barriers to insulin initiation and intensification and how to overcome them. Int J Clin Pract Suppl 164 (2009), 6–10.
de Pablos-Velasco, P., Parhofer, K.G., Bradley, C., Eschwege, E., Gonder-Frederick, L., Maheux, P., et al. Current level of glycaemic control and its associated factors in patients with type 2 diabetes across Europe: data from the PANORAMA study. Clin Endocrinol (Oxf) 80 (2014), 47–56.
Simon, D., de Pablos-Velasco, P., Parhofer, K.G., Gonder-Frederick, L., Duprat Lomon, I., Vandenberghe, H., et al. Hypoglycaemic episodes in patients with type 2 diabetes—risk factors and associations with patient-reported outcomes: The PANORAMA Study. Diabetes Metab 41 (2015), 470–479.
